

How to screen for dysphagia in Parkinson's disease?

The Munich Dysphagia Test (MDT-PD) – a patient reported outcome questionnaire

Janine A Simons¹, Annika Waldmann¹, Urban M Fietzek²

¹ Institute for Social Medicine and Epidemiology, Universität zu Lübeck, Germany ² Centre for Parkinson's Disease and Movement Disorders, Schön Klinik, Munich, Germany

OBJECTIVE

- To evaluate the diagnostic performance of a newly developed dysphagia-screening questionnaire specified for patients with Parkinson's disease (PD).

BACKGROUND

- Oropharyngeal dysphagia as well as manifested aspiration frequently occur in patients with PD.
- Especially symptoms of the early clinical syndrome are still widely underdiagnosed, leading to significant threats to health, such as aspiration pneumonia, malnutrition, or reduced quality of life.
- There are no disease-specific and sufficiently validated screening procedures available.

METHODS

- The project comprised the development (N=105) and validation phases (N=82) of the Munich Dysphagia Test (MDT-PD, **Figure 1**).
- PD patients were recruited at a German center for movement disorders; enrollment for validation purpose was consecutively (in-/out-/day-care patients).
- Patients were assessed by clinical swallowing tests and fiberoptic endoscopic evaluation using standardized protocols (90ml water, ½ slice crusted bread, dry cookie, placebo pills).
- They were assigned to the groups 'no dysphagia (N)', 'oropharyngeal dysphagia (OD)', and 'dysphagia with penetration/aspiration (P/A)' along their severity grades of underlying rating-scales.
- Resulted criteria sum scores were compared against the results of the previously answered MDT-PD.
- The internal consistency was evaluated and the diagnostic quality computed for the detection of noticeable OD, or the risk of aspiration, and proved by cross-validation.

Figure 2 MDT-PD self-reporting outcome questionnaire





Figure 1 MDT-PD project phases (N = 187)

Phase I – Development
Part 1 – Questionnaire and diagnostic scale construction Step 1 – Questionnaire item generation/semi-structured interviews, N = 10+10*: initial 46-item version Step 2 – Psychometric tests/questionnaires, N = 20; modification and reduction to: 39-item version Step 3 – Parameter generation for clinical symptom scale and FEES incl. gold standard (10+19 parameters), N = 20* *healthy relatives of PD patients
Part 2 – Pilot study, N = 45 Step 1 – Testing construct validity and proceeding feasibility/precision study of questionnaire and diagnostic scale drafts Step 2 – Questionnaire item reduction to final 26-item version Step 3 – Diagnostic scales modification (29 parameters)
Phase II – Validation
Validation study, N = 82 <ul style="list-style-type: none"> Reliability analysis Dysphagia classifications & criteria sum score Validation procedure: weighting of items, correlation with criteria sum score, discriminatory analyses of items, determination of cut-off values, cross-validation
Add on <ul style="list-style-type: none"> German to English translation by decentering method Web-app programming for result evaluation

* **Web app** runs on all popular operating systems, browsers, and devices, **Outcome classifications:** no noticeable dysphagia, noticeable oropharyngeal dysphagia, dysphagia with risk of penetration/aspiration

Figure 3 MDT-PD web app*



RESULTS

- The 26-item questionnaire MDT-PD (**Figure 2**) showed high internal consistency (Cronbach's Alpha 0.91).
- Patients of the validation study (N=82) aged 70.9 ± 8.7 (mean \pm SD), were Hoehn & Yahr stage of 3 in median and scored 29.5 ± 13.3 in the UPDRS motor part.
- Dysphagia prevalence was 73% (44% OD, 29% P/A).
- A positive correlation was found between the criteria sum score and weighted MDT-PD sum score ($r = 0.70$, $p < 0.001$).
- Diagnostic quality to discriminate between N and OD as well as N and P/A resulted in good to very high values, with similar results in cross-validation (**Table 1**).

Table 1 MDT-PD Diagnostic quality

Dysphagia groups	not noticeable (N) vs. noticeable (OD)		not noticeable (N) vs. risk of aspiration (P/A)	
	Validation	Cross-validation	Validation	Cross-validation
Sens (CI)	82.4% (0.696–0.952)	82.4% (0.696–0.952)	90.0% (0.775–1.025)	90.0% (0.775–1.025)
Spec (CI)	71.4% (0.521–0.907)	61.9% (0.411–0.827)	85.7% (0.707–1.007)	81.0% (0.642–0.978)
PPV / NPV	82.4% / 71.4%	77.8% / 68.4%	87.0% / 90.0%	81.8% / 89.5%
YI	0.54	0.44	0.76	0.71
LR+ / LR-	2.9 / 0.2	2.2 / 0.3	6.3 / 0.1	4.7 / 0.1
Cut off	3.65	3.63	4.79	4.75

Sensitivity (Sens), specificity (Spec), confidence interval (CI), positive/negative predictive value (PPV/ NPV), Youden index (YI), likelihood ratio+/- (LR+/-); cut-off point (Cut off)

CONCLUSION

- In medical practice the MDT-PD¹ can be used for a valid detection of dysphagia and initial graduation of dysphagia severity.
- Patient's answers can be easily evaluated using a web application (**Figure 3**); clinical interpretation is provided additionally.
- Questionnaire & web app is available in German & English language.

